PR Science Signs Exclusive Sales Agreement for PLLA Filler 'Ollidia' in Six European Countries

[Asia Economy Reporter Hyunseok Yoo] PRP SCIENCE, a filler manufacturing specialist company, announced on the 10th that its poly-L-lactic acid (PLLA) filler 'Olidia,' which uses FDA-approved raw materials, has signed exclusive sales contracts in six European countries. Having proven its safety and efficacy with the Ministry of Food and Drug Safety's product approval last July, the company plans to actively pursue sales contracts domestically starting this year.

Olidia, developed with domestic technology by PRP SCIENCE, promotes collagen production and shows effects after 4 to 6 weeks, improving wrinkles. Composed of 80% uniform particles, it maintains consistent volume well and offers excellent injection feel. Its advantage is the fast preparation time, with injection water and suspension time taking about 30 minutes, allowing same-day procedures.

Olidia is the second PLLA filler to receive product approval in Korea following 'Sculptra,' a representative PLLA filler developed by multinational pharmaceutical company Sanofi Aventis, and it is the third in the world to obtain European CE certification.

Clinical trials for domestic product approval were conducted at two university hospitals in Korea, comparing 109 cases involving Olidia and Sculptra. The study evaluated the temporary improvement effect and safety on facial nasolabial folds. The results demonstrated new tissue formation and promoted collagen production at the filler injection sites, confirming that Olidia and Sculptra share identical physicochemical properties and degradation profiles.

A PRP SCIENCE official stated, "The filler market is expected to establish itself as a polymer-based market within the next few years, with the market potential greatly expanding around biodegradable polymer materials such as PLLA fillers. This is evident from the global and domestic market share expansion of Sculptra, an existing PLLA filler."

He added, "Olidia has currently signed exclusive sales contracts in six European countries and plans to pursue sales contracts domestically starting January this year. In China, after obtaining certification from the National Medical Products Administration (NMPA), contracts exceeding 50 billion KRW over five years are underway, and in Brazil, after approval from the National Health Surveillance Agency (ANVISA), contracts exceeding 30 billion KRW over five years in the South American market are progressing, so significant sales are expected."

Furthermore, he emphasized, "Not only Olidia, recently launched, but also various skin booster products will be additionally developed and released timely to meet the needs of the anti-aging market. Our goal is to enter the global top 2 polymer filler manufacturers, focusing on differentiated polymer material product lines compared to other companies."

This content was produced with the assistance of AI translation services.